Novel Drug Testing Technology Featured at AACC 2015
By LabMedica International staff writers Posted on 23 Aug 2015 |
The 2015 AACC Meeting & Clinical Lab Expo (July 26-30; Atlanta, GA, USA) featured new science and novel technology in all areas of clinical diagnostics. Market researcher Kalorama Information (New York City, NY, USA) attends the AACC meeting annually and notes developments for its reports on the in vitro diagnostic (IVD) market. Here, Kalorama notes the presentation of a unique approach to drugs-of-abuse testing via a new technology for urine-based drug testing.
“UR Code” by Marker Test Diagnostics, Inc. (Scottsdale AZ, USA) was designed to eliminate false-negative results that occur upon manipulation and observed-collection of samples, while providing an accurate and secure solution. It addresses sample integrity, one of the main issues in drug testing, as even under observation, sample adulteration or substitution is very common. UR Code is an orally taken marker that internally "bar-codes" a subject's urine. As observed-collections are invasive, inefficient, expensive, and require extensive organizational effort, UR Code aims to make sample substitution impossible while eliminating the need to supervise urine collection.
UR Code is a soft-gel capsule that provides a marker to code a person's urine. This code can only be detected through liquid chromatography-tandem mass spectrometry (LC-MS/MS). Neither the person providing the sample nor the soft-gel provider can predict which UR Code combination is given. The soft-gel capsule contains polyethylene glycol, a substance on the Food and Drug Administration's (FDA) list of inactive ingredients, cleared for humans and without side effects. Polyethylene glycols are not naturally found in urine and they have different molecular weights that enable the creation of 1,000 different marker types.
The test-subject takes the UR Code capsule under supervision. UR Code is absorbed, not metabolized, and quickly cleared through the kidneys. Thirty minutes later, urine can be collected without supervision. The laboratory then tests, using LC-MS/MS, whether the sample contains the correct code combination.
Kalorama’s latest comprehensive IVD market report—The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 9th Edition—covers not only drugs-of-abuse testing and urinalysis but all major segments of clinical lab testing. The information presented in this report is derived on publicly available information sources. The analysis is based on the author's IVD industry knowledge combined with literature searches and interviews with industry professionals and experts. Hundreds of companies were tracked. This research is compiled along with the input of industry experts to produce an unparalleled vision of the IVD industry. The report includes market estimates and forecasts to 2018.
Related Links:
Kalorama Information
The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 9th Edition
2015 AACC Annual Meeting & Clinical Lab Expo
“UR Code” by Marker Test Diagnostics, Inc. (Scottsdale AZ, USA) was designed to eliminate false-negative results that occur upon manipulation and observed-collection of samples, while providing an accurate and secure solution. It addresses sample integrity, one of the main issues in drug testing, as even under observation, sample adulteration or substitution is very common. UR Code is an orally taken marker that internally "bar-codes" a subject's urine. As observed-collections are invasive, inefficient, expensive, and require extensive organizational effort, UR Code aims to make sample substitution impossible while eliminating the need to supervise urine collection.
UR Code is a soft-gel capsule that provides a marker to code a person's urine. This code can only be detected through liquid chromatography-tandem mass spectrometry (LC-MS/MS). Neither the person providing the sample nor the soft-gel provider can predict which UR Code combination is given. The soft-gel capsule contains polyethylene glycol, a substance on the Food and Drug Administration's (FDA) list of inactive ingredients, cleared for humans and without side effects. Polyethylene glycols are not naturally found in urine and they have different molecular weights that enable the creation of 1,000 different marker types.
The test-subject takes the UR Code capsule under supervision. UR Code is absorbed, not metabolized, and quickly cleared through the kidneys. Thirty minutes later, urine can be collected without supervision. The laboratory then tests, using LC-MS/MS, whether the sample contains the correct code combination.
Kalorama’s latest comprehensive IVD market report—The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 9th Edition—covers not only drugs-of-abuse testing and urinalysis but all major segments of clinical lab testing. The information presented in this report is derived on publicly available information sources. The analysis is based on the author's IVD industry knowledge combined with literature searches and interviews with industry professionals and experts. Hundreds of companies were tracked. This research is compiled along with the input of industry experts to produce an unparalleled vision of the IVD industry. The report includes market estimates and forecasts to 2018.
Related Links:
Kalorama Information
The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 9th Edition
2015 AACC Annual Meeting & Clinical Lab Expo
Latest AACC 2015 News
- Automated Molecular Diagnostics System Presented at AACC 2015
- Portable Molecular Diagnostics System Unveiled At 2015 AACC
- Expanded Steroid Control Launched at the 2015 AACC Annual Meeting
- Innovative New Technology to Provide Plastic-Exterior Components with Glass Interior, Presented at AACC 2015
- Eco-Friendly Immunoassay Reagents Featured at AACC 2015
- Low Cost Point-of-Care DNA Amplification Test for Chlamydia Infection Demonstrated at the 2015 AACC Annual Meeting
- Inexpensive Multipurpose Point-of-Care Analyzer Unveiled at 2015 AACC Annual Meeting
- State-of-the-Art Automated Laboratory Systems Highlighted at the 2015 AACC Annual Meeting
- Siemens Showcases Multiple New IVD Solutions at AACC 2015
- New HPLC Quadruples Clinical Throughput Capabilities, Displayed at AACC 2015
- Diagnostic Test that Measures Active Renin in Hypertension Displayed at the 2015 AACC Annual Meeting
- Hair Testing May Offer Insights into Asthma-Related Complications in Pregnancy
- Two Newly Developed Tests May Better Diabetes Diagnosis and Monitoring
- CE Marking of Theranostic Monitoring Test Announced at 2015 AACC Annual Meeting
- Ebola Rapid Lateral Flow Test Previewed at the 2015 AACC Annual Meeting
- AACC: Better Quality and Patient-Friendliness Needed in Direct Testing